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generation antipsychotics (SGAs) were prescribed regardless of mono-therapy or 
combination therapy. Risperidone [n= 17 (56.7%)] was most frequently prescribed, 
followed by aripiprazole [n= 7 (23.3%)] and olanzapine [n= 5 (16.7%)]. Haloperidol was 
the predominant first generation antipsychotic (FGA) prescribed [n= 3(10%)]. Of the 
patients on combination therapy [n= 12], most [n= 10 (83.3%)] were on combination 
of two or more SGAs. A majority [n= 18(60%)] of the patients had an unchanged 
outcome at the time of discharge. ConClusions: The results of the study indicate 
that the therapy prescribed does not meet the clinical goals for the patients. A larger 
study is required to assess the prescription patterns and the predictors of outcomes 
among schizophrenics in the Indian population.
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10-Year Medication utilization trends for stiMulant, 
antidePressant, and antiPsYcHotic Medications in texas Medicaid 
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objeCtives: The objective of this study was to determine the medication utiliza-
tion rates of stimulant, antidepressant, and antipsychotic medications during the 
period 2002-2012 in Texas Medicaid children aged 0 to 3 years old. Methods: Texas 
Medicaid prescription claims data from 2002 to 2012 were analyzed for patients 
who were 3 years old or younger. Specifically, stimulant, antidepressant, and antip-
sychotic prescription claims were assessed to determine trends by age and gen-
der. Results: The number of Texas Medicaid patients 3 years old and younger 
ranged from about 830,000 in 2002 to 1.3 million in 2012. From 2002 to 2012, the 
percent of children 3 years old and under prescribed stimulants increased from 
0.10% to 0.11% (highest year 2011 at 0.14%). For antidepressants, there was also an 
increase from 0.02% to 0.03% (highest year 2011 at 0.04%). In contrast, the percent 
of antipsychotic users decreased from 0.02% to less than 0.01% (highest year 2004 
at 0.02%). On average, over the 10-year period, the majority of utilizers were male 
(73.6% stimulants, 69.4% antidepressants, and 74.6% antipsychotics), and percent-
ages were similar from year to year. Three-year-olds represented the majority of 
medication users for each medication category, where they constituted more than 
75.0% of all users, at any point from 2002 to 2012. For patients 2 years old or younger, 
the stimulant utilization rate followed a generally steady decrease over the 10-year 
period, while the antipsychotic and antidepressant utilization rates increased from 
2002, peaked (around 2006 and 2010, respectively), and then decreased thereaf-
ter. ConClusions: The use of stimulant and antidepressant medications in Texas 
Medicaid children three years old and younger increased from 2002 to 2011 but then 
decreased in 2012. The use of antipsychotic medications in this age group peaked 
in 2004 and, overall, has been decreasing since then.
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objeCtives: Aripiprazole and risperidone are the only two FDA-approved drugs 
for treating autism. No study has looked at their actual use and their costs in real-
world settings. This will be the first study to examine the actual use of aripiprazole 
and risperidone in children with autism using insurance claims data. Methods: 
Nationwide 2008-2010 insurance claims data from the MarketScan research data-
base were used. Privately insured children with autistic spectrum disorders (ASD) 
were identified using diagnosis codes. Costs were measured as what insurance 
companies paid. Results: Though aripiprazole became the second approved antip-
sychotic drug for autism in 2009 after risperidone in 2002, the rate of aripiprazole 
use in 2010 (30%) barely increased from that in 2008 (27%) before the approval, 
which nevertheless was a huge jump from a rate of less than 5% in 2003 reported in 
another study. The rate of risperidone use (47%) was not affected after the approval 
of aripiprazole. The first generic formulation of risperidone was approved in mid-
2008, and generic risperidone use instantly went from zero to 50% within one month, 
reaching 90% by mid-2009. The average aripiprazole cost per child increased from 
$2986 in 2008 to $3534 in 2010, whereas the average risperidone cost decreased from 
$1481 in 2008 to $715 in 2010 due to use of the generic formulation. ConClusions: 
Because use of aripiprazole only minimally increased after approval suggests that 
the market for aripiprazole in autism may have been close to saturation before 
approval due to off-label use. In contrast, patients and clinicians responded imme-
diately to the debut of generic risperidone by switching to it from the same branded 
drug, but they did not switch from the more expensive branded aripiprazole to 
generic risperidone, even though the literature suggests similar efficacy and safety 
of the two drugs for autism.
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objeCtives: The objective of this study was to assess the treatment patterns 
of long-acting injectable antipsychotics (LAI-AP), notably in terms of treatment 
persistence and compliance, in a real life setting, using the provincial pub-
lic drug reimbursement program database of the Régie de l’assurance maladie du 
Québec(RAMQ). Methods: Patients with a diagnosis of schizophrenia/schizoaf-
fective disorder, who were incident users (no use in the previous 12 months) of a 
LAI-AP prescribed between January 1st 2008 and March 31st2012, at least 20 years 
old, and with continuous enrolment in the database during the study period were 
selected. Concomitant use of oral antipsychotics and treatment adherence with 
LAI-AP were analyzed. Persistence was estimated in terms of treatment duration. 
The study objective is to measure the impact of state PDMP characteristics on the 
dispensing of opioids and benzodiazepines to Medicaid beneficiaries. Methods: 
Medicaid dispensing and reimbursement data for each state (1990-2011) was 
obtained from the Medicaid Drug Rebate Program. Opioid and benzodiazepine pre-
scriptions dispensed were isolated from the data and standardized to morphine 
milligram equivalents (MMEs) and diazepam milligram equivalents (DMEs), respec-
tively. Data was merged with state PDMP characteristics obtained from the National 
Alliance of Model State Drug Laws and several potential explanatory variables were 
identified; including, operational program, compulsory provider participation, inter-
state data sharing, and proactive notification of potential abuse. A random effects 
model using GLS regression was employed to generate estimates of the impact of 
state PDMP characteristics over time on MMEs dispensed of Schedule II opioids 
(CII), dispensing of Schedule III opioids (CIII), and DMEs of benzodiazepines. MMEs, 
DMEs, and Medicaid reimbursement dollars per MME dispensed were log trans-
formed. Results: States with operational PDMPs dispensed on average 0.29 fewer 
logged MMEs of CII opioids (p< 0.05). States with PDMPs housed in law enforcement 
agencies dispensed 0.11 more logged MMEs of CII opioids (p< 0.05) on average and a 
1-unit increase in Medicaid reimbursement resulted in 0.39 more logged MMEs of 
CII opioids dispensed (p< 0.001). States with PDMP interstate data sharing dispensed 
0.11 more logged MMEs of CII opioids (p< 0.05). Results for CIII opioids and benzo-
diazepines were similar. ConClusions: States with operational PDMPs dispense 
fewer CII and CIII opioids, and benzodiazepines, to Medicaid patients. The amount 
of Medicaid reimbursement and data sharing with other states is associated with 
increased dispensing, but compulsory PDMP use and proactive reporting to health 
providers were not found to impact dispensing.
PMH78
Medicaid forMularY restrictions and exPenditures for Patients 
witH Major dePressive disorder
Seabury S1, Lakdawalla D.N.2, Walter D.3, Hayes J.4, Gustafson T.5, Shrestha A.6, Goldman D.P.2
1Keck School of Medicine of USC, Los Angeles, CA, USA, 2University of Southern California, Los 
Angeles, CA, USA, 3Takeda Pharmaceuticals America, Inc, 4National Network of Depression 
Centers, 5Arnold & Porter, LLP, 6Precision Health Economics, Los Angeles, CA, USA
objeCtives: Many state Medicaid programs have implemented restrictive formu-
lary policies designed to reduce prescription drug spending. However, restrictions 
limiting access to antidepressants could disrupt therapy for patients with major 
depressive disorder (MDD). This study’s objective is to examine the effect of for-
mulary restrictions on state spending and MDD patient outcomes. Methods: We 
used data on patient outcomes from 24 state Medicaid programs from 2001-2008. 
Outcome variables included MDD-related hospitalizations and inpatient, pharmacy 
and total spending. National data on employment and social program participa-
tion for Medicaid patients, including Social Security Disability Insurance (SSDI) and 
Supplemental Security Income (SSI) were collected from the American Community 
Survey (ACS) for 2008-2011. We linked these data to information on prior authoriza-
tion and step therapy targeting antidepressants use in Medicaid by state and year. 
We used regression to identify associative effects of state policies on outcomes 
conditional on patient characteristics. Results: Prior authorization was associated 
with a 5.7% increase in the annual, per-patient rate of MDD-related hospitaliza-
tions (p= 0.048); prior authorization and step therapy combined were associated 
with a 16.6% increase (p= 0.075). Inpatient expenditures also increased for MDD 
patients exposed to formulary restrictions on antidepressants: expenditures were 
5.8% higher (p= 0.369) for patients exposed to prior authorization alone and 18.4% 
higher (p= 0.014) for those exposed to both prior authorization and step therapy. 
There was no statistically significant relationship between formulary restrictions 
and either pharmacy spending or total spending. Prior authorization was associ-
ated with a 1.8% (p< 0.001) decrease in labor force participation among Medicaid 
patients. There was no significant association with SSI or SSDI receipt, but prior 
authorization was associated with increased receipt of other public assistance 
(p< 0.001). ConClusions: Formulary restrictions on antidepressants in Medicaid 
are not associated with lower spending for patients with MDD, and may be associ-
ated with worse health outcomes and reduced labor force participation.
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objeCtives: The objective of this study was to describe the prescription pattern 
of antipsychotics among schizophrenia patients in a psychiatric hospital. The sec-
ondary objective was to describe the patient characteristics. Methods: A retro-
spective observational study was conducted from January, 2010 – January, 2011. All 
patients with a clinical diagnosis of schizophrenia who had been hospitalized during 
the study period were followed for one year post-hospitalization. Data on patient 
demographics, disease onset, clinical diagnosis, prescription medications and clini-
cal outcomes were obtained from the medical records. Outcomes were defined as 
per medical records as improved or unchanged upon discharge. Results: Thirty 
patients were hospitalized from January 2010 to January 2011 with a clinical diagno-
sis of schizophrenia. The population was unequally distributed in terms of gender. 
The mean age of the patients was 36.66 ± 9.24 years. Most patients [n = 17(53%)] had 
a family history of schizophrenia. Paranoid schizophrenia was the most common 
diagnosis among patients [n= 15 (50%)] followed by un-differentiated schizophre-
nia [n= 4(13.3%)], simple schizophrenia [n= 2 (13.3%)], catatonic schizophrenia [n= 2 
(13.3%)], hebephrenic schizophrenia [n= 2 (13.3%)]. Monotherapy with respect to 
antipsychotics was seen among a majority of the patients [n= 17(56.66%)]. Second 
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dents in the treatment of dementia-related psychosis particularly in two forms: i) 
off-label prescribing-i.e., prescribing AAPs for an unapproved indication against 
FDA-issued warnings on the product label and, ii) polytherapy-i.e., concurrent use 
of two or more AAPs contrary to evidence-based treatment guidelines. Methods: 
The study utilized a sample of nursing home residents, obtained from 2004 National 
Nursing Home Survey database (NNHS). The study sample included residents aged 
65 and over, with at least one prescription for a currently marketed AAP and having 
a primary diagnosis of dementia in accordance with ICD-9 codes. Off-label prescrib-
ing and polytherapy with AAPs served as the study dependent variables, along with 
a systematic analysis of demographic, clinical, social and other factors. Results: 
Out of 13507 nursing home residents in the database, 4955 individuals (36.6%) had 
a primary diagnosis of dementia. About 32% of these were prescribed at least one 
AAPs and less than 1% also used an additional AAPs. Elderly who were aged 80 years 
and over was the group with most prescriptions for AAPs (49%). In a specific popula-
tion affected by schizophrenia and bipolar disorder, where AAP polytherapy may 
be clinically justified (58%) had a prescription for at least one AAP, with olanzapine 
(28%) being the most prescribed. About 7% of this population was also concurrently 
taking at least two AAPs. ConClusions: Overall, the use of polytherapy appears to 
be negligible in the sample diagnosed with dementia. However, in nursing home res-
idents with co-morbidities, polytherapy with AAPs appears to be more pronounced 
compared to the larger dementia population. In addition, off-label prescribing seems 
widespread particularly in older population diagnosed with dementia.
sYsteMic disorders/conditions – clinical outcomes studies
PsY1
assessMent of structured eMr data’s abilitY to Predict or identifY 
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objeCtives: Assess ability of structured electronic medical record (EMR) data to 
predict or identify a measure of Clinician Labeled Opioid Abuse (CLOA) derived 
from clinicians’ unstructured EMR notes for patients on Chronic Opioid Therapy 
(COT). Methods: Study subjects included 2,752 chronic non-cancer pain patients 
initiating COT during 2008-10 at Group Health Cooperative (Seattle, WA) who 
received at least 2 quarters of COT (≥ 70 days’ supply of an opioid in a quarter) 
within a one-year period. CLOA was derived using Natural Language Processing 
(NLP) techniques based on a custom dictionary of 792 terms to identify mentions 
of opioid addiction, abuse, and overuse written in the clinician’s free text clinical 
notes in the patient’s EMR. CLOA was validated by computer-assisted manual 
review of NLP positive clinical EMR notes. We developed an opioid abuse risk score 
from structured EMR data for the two year period prior to COT Initiation (“prior” 
model), and an opioid abuse risk score from structured EMR data from the quar-
ter of COT initiation through December 2012 (“concurrent” model). Using logistic 
regression, we predicted CLOA status from the prior and concurrent opioid abuse 
risk scores in both learning and validation samples. Results: In the sample, 
100 (3.6%) patients had CLOA, but only 51% of these patients had an ICD-9 diag-
nosis of opioid abuse in concurrent EMR data. The “prior” risk score from struc-
tured data predicted CLOA with an area under the curve of 0.75 in the learning 
sample and 0.74 in the validation sample, while the “concurrent” risk score 
developed from structured data identified CLOA with an area under the curve of 
0.84 in the learning sample and 0.88 in the validation sample. ConClusions: 
Preliminary results suggest moderate ability of prior structured EMR data to pre-
dict CLOA and good ability of concurrent structured EMR data to identify patients 
with CLOA.
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objeCtives: To estimate the overall response rate [Complete Remission-(CR), 
Partial Remission-(PR), Marrow-CR (MCR)] and Hematologic improvement-(HI) accord-
ing to the International Working Group 2006 criteria to treatment with azacitidine 
amongst patients with Intermediate-2 or High- risk Myelodysplastic Syndromes 
(MDS), in a real world setting in Greece. Methods: A nationwide, retrospective 
chart review study was conducted, based on 17 Hematology departments of Hospitals 
throughout the country. In one single visit the physicians recorded all the pertinent 
data available in the patient’s medical records. In accordance with the inclusion crite-
ria, patients recruited were ≥ 18 years of age and alive at the time of their data collec-
tion, had completed at least one evaluation after azacitidine treatment initiation, and 
received at least one cycle of azacitidine treatment regardless of outcome. Patients also 
gave signed informed consent for blinded analyzation of their medical data. Eligible 
patients had been treated with azacitidine under the terms of the locally approved 
indication (75 mg/m2 SC per day for 7 days every 28 days). Results: 53% of the partici-
pating physicians were located in Attica and enrolled 36% of patients. The mean age 
of 88 patients was estimated at 72.8+ 8.2, with 83% of them aged > 65 years, while the 
male/female ratio was 2.5. The overall response rate was determined at 37.7% and was 
higher for High-risk MDS patients (46.2%) compared with Intermediate-2 patients 
(35.5%). Among the responders, 87% had Refractory Anemia with Excess Blasts 
-RAEB-2, 8.7% had RAEB-1 and 4.3% had Refractory Cytopenias with Unilineage 
Dysplasia. The median number of treatment cycles received to achieve CR, PR, or 
Compliance was calculated during the year after the initiation of the LAI-AP using 
the medication possession ratio (MPR). Patients were considered compliant if they 
had a MPR of at least 0.80. Treatment compliance to oral antipsychotics used in 
the year prior the initiation of the LAI-AP was also evaluated. Results: A total of 
1,992 patients met the inclusion criteria. The mean age was 43.5 years (SD= 14.3) 
and 66.2% of the patients were male. A total of 546 patients (27.4%) received an oral 
antipsychotic at the first date of dispensation of LAI-AP. The average persistence 
with LAI-AP was 217.2 days (SD= 144.2). The mean MPR over the 1-year period fol-
lowing the initiation of LAI-AP was 0.58 (SD= 0.35) for the overall cohort, with 37.5% 
of patients being compliant with a MPR of 0.80 or more, while in the year before 
the initiation of LAI-AP treatment compliance with oral antipsychotics was 29.0% 
(p< 0.001). ConClusions: Treatment persistence and compliance represent signifi-
cant issues in the treatment of schizophrenia/schizoaffective disorders. The initia-
tion of a LAI-AP significantly improved treatment compliance among these patients.
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Lafeuille M.H.1, Fortier J.1, Grittner A.M.1, Muser E.2, Fastenau J.2, Duh M.S.3, Lefebvre P.1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Janssen Scientific Affairs, LLC, Titusville, NJ, 
USA, 3Analysis Group, Inc., Boston, MA, USA
objeCtives: To analyze treatment patterns of patients receiving paliperidone 
palmitate (PP) in the inpatient setting. Methods: Hospital discharge and billing 
records from the Premier Perspective Comparative Hospital Database (1/2009-3/2012) 
were analyzed for adult patients who had a hospitalization (index hospitalization) 
with a schizophrenia diagnosis (ICD-9: 295.x), and who received their first inpatient 
PP treatment without evidence of prior inpatient treatment with other long-acting 
antipsychotics (AP). Patients with only a schizoaffective disorder diagnosis (ICD-9: 
295.7) during index admission and patients discharged to a psychiatric institute 
were excluded. Length of stay (LOS), time to first PP, and PP dosage frequency and 
strength were used to describe treatment patterns. Statistical comparisons were 
conducted between patients receiving one versus multiple PP doses during hospi-
talization using Wilcoxon rank-sum tests. No adjustment was made for multiplic-
ity. Results: A total of 374 hospitalized patients treated with PP were identified. 
Mean LOS was shorter for one-dose (N= 228) relative to multiple-dose (N= 146) 
patients (11.4 vs. 16.7 days, p< 0.0001) and mean time to first PP was 7.7 and 6.5 
days (p= 0.0161), respectively. Earlier first PP administration was associated with 
shorter LOS (Spearman rank correlation tests: 0.6953 (p< 0.0001) for the one-dose 
and 0.5897 (p< 0.0001) for the multiple-dose cohorts). Among one-dose patients, 
48.2% received a first injection of 234mg. Most multiple-dose patients received a 
first dose of 234mg (70.5%) followed by 156mg (71.2%) as a second dose. The mean 
(SD) time to second PP injection was 5.93 (2.59) days. ConClusions: 39% (146 of 
the 374 patients) of PP patients received multiple PP doses during their inpatient 
stay and had a shorter mean time to treatment initiation compared to one-dose 
patients. Most of these patients received the labeled initiation regimen (234mg 
followed by 156mg dose). In both dose cohorts, shorter time to treatment initiation 
was associated with shorter LOS.
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objeCtives: The abuse of prescription opioids in the United States leads to more 
than 16,000 deaths each year, about one death every 35 minutes (Paulozzi et al., 
2011). Our objectives are to develop a novel social network analysis methodology 
to identify and measure prescription drug abuse. Methods: Prescription data were 
retrieved from a large insurance provider for the state of KY and consisted of pre-
scriber IDs, patient IDs, and location across a spectrum of drugs (Schedule drugs, 
and a set of ‘control group’ products). Network abstractions of the prescribers were 
generated. Surrogate testing in conjunction with community structure detection 
algorithms were used to investigate possible non-random structure of the prescrip-
tion patterns and identify aberrant prescribers. The results of the network analysis 
were visualized using Geo-spatial layouts based on latitude/longitude. Results: 
Network abstractions of the prescribers revealed intricate wiring patterns across 
schedule drugs unlike those of the drugs in the control group. Surrogate testing 
clearly established significant non-random structure in these networks in contrast 
to those that can be generated by random graph realizations. Aberrant prescrib-
ers were subsequently flagged. Non-random structure was accompanied were 
accompanied by highly connected prescribers and hub-like structure. Geo-spatial 
layout of the scheduled drug networks revealed the dominant prescribers to be 
spread across major cities and patient movements across prescribers over large dis-
tances. Lack of wiring across the drugs in the control group indicated that patients 
taking these drugs do not move across prescribers unlike those taking schedule 
drugs. ConClusions: Our results provide system-level insights into prescription 
patterns and supplements traditional approaches that investigate aggregate statisti-
cal measures across the prescribers in isolation. Its ability to identify non-random 
structure and discern such structures across the various drug classes is noteworthy. 
We believe the proposed approach may prove to be a useful tool in implementing 
effective policies to reduce prescription drug abuse, diversion, and overdose
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objeCtives: Inappropriate use of Atypical Antipsychotics (AAPs) in elderly nurs-
ing home residents is a growing problem in geriatric medicine. The current study 
investigated clinically irrational prescribing of AAPs to elderly nursing home resi-
